

ANALYSIS
AUGUST 2022

Prepared by

Mark Zandi
Mark.Zandi@moodys.com
Chief Economist

Bernard Yaros
Bernard.Yarosjr@moodys.com
Assistant Director/Economist

Chris Lafakis
Chris.Lafakis@moodys.com
Director

Contact Us

Email
help@economy.com

U.S./Canada
+1.866.275.3266

EMEA
+44.20.7772.5454 (London)
+420.224.222.929 (Prague)

Asia/Pacific
+852.3551.3077

All Others
+1.610.235.5299

Web
www.economy.com
www.moodysanalytics.com

Assessing the Macroeconomic Consequences of the Inflation Reduction Act of 2022

Introduction

Lawmakers appear close to passing into law the Inflation Reduction Act of 2022. The legislation is born out of the Build Back Better agenda that President Biden proposed more than a year ago. It raises nearly \$750 billion over the next decade through higher taxes on large corporations and wealthy individuals and lower Medicare prescription drug costs, to pay for nearly \$450 billion in tax breaks and additional government spending to address climate change and pay for lower health insurance premiums for Americans benefiting from the Affordable Care Act. The remaining more than \$300 billion goes to reducing the federal government's future budget deficits. Broadly, the legislation will nudge the economy and inflation in the right direction, while meaningfully addressing climate change and reducing the government's budget deficits.

Assessing the Macroeconomic Consequences of the Inflation Reduction Act of 2022

BY MARK ZANDI, BERNARD YAROS AND CHRIS LAFAKIS

Lawmakers appear close to passing into law the Inflation Reduction Act of 2022. The legislation is born out of the Build Back Better agenda that President Biden proposed more than a year ago. It raises nearly \$750 billion over the next decade through higher taxes on large corporations and wealthy individuals and lower Medicare prescription drug costs, to pay for nearly \$450 billion in tax breaks and additional government spending to address climate change and pay for lower health insurance premiums for Americans benefiting from the Affordable Care Act (see Table 1). The remaining more than \$300 billion goes to reducing the federal government's future budget deficits (see Chart 1). Broadly, the legislation will nudge the economy and inflation in the right direction, while meaningfully addressing climate change and reducing the government's budget deficits.

Table 1: Inflation Reduction Act of 2022

Static budget effect, calendar yr, \$ bil


	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2022-2027	2022-2031
Net budget effect	0.2	-27.2	-7.4	6.6	-1.2	-18.9	-42.3	-57.3	-73.2	-84.0	-29.1	-304.8
Investments	0.1	24.7	43.7	56.6	48.1	52.1	55.1	52.6	50.5	49.6	173.2	433.0
Climate and energy provisions	0.1	12.6	20.7	32.5	43.3	52.1	55.1	52.6	50.5	49.6	109.2	369.0
Extension of enhanced ACA premium subsidies	0.0	12.1	23.0	24.0	4.9	0.0	0.0	0.0	0.0	0.0	64.0	64.0
Pay-fors	0.1	-52.0	-51.1	-50.0	-49.3	-71.1	-97.4	-109.8	-123.6	-133.6	-202.3	-737.8
15% corporate alternative minimum tax	0.0	-50.3	-47.4	-31.8	-26.8	-26.8	-29.0	-31.4	-33.7	-36.0	-156.2	-313.1
Prescription drug pricing reforms	0.0	-2.0	-3.0	-13.1	-12.1	-28.4	-47.6	-53.3	-61.5	-66.6	-30.2	-287.6
IRS funding to close the tax gap	0.1	1.6	0.8	-3.6	-9.1	-14.4	-19.3	-23.7	-26.9	-29.5	-10.2	-124.0
Carried interest loophole	0.0	-1.2	-1.6	-1.5	-1.4	-1.4	-1.4	-1.5	-1.5	-1.5	-5.7	-13.0

Sources: CBO, JCT, Moody's Analytics

Inflation Reduction Act

The Inflation Reduction Act is a scaled back version of part of the Build Back Better agenda proposed by Biden early in his administration. When the BBB was first proposed, it included fiscal support for the

Chart 1: Much to Like in the Inflation Reduction Act



Sources: CBO, JCT, Moody's Analytics

nation's infrastructure, a range of social programs, and climate change. In their entirety, these BBB investments would have cost nearly \$4.5 trillion over a 10-year budget horizon, mostly paid for with tax increases on large corporations and high-income, wealthy households. A version of the infrastructure legislation became law last summer, and if the Inflation Reduction Act gets across the legislative finish line, Biden will have gotten almost one-quarter of the BBB agenda that he had originally proposed to Congress into law.

Climate change

The bulk of the investments in the Inflation Reduction Act, costing an estimated \$370 billion over 10 years, are directed toward promoting clean energy and climate resilience. Two-thirds of this amount is in the form of federal tax credits that extend, enhance or create incentives to produce electricity from clean energy sources, invest in renewable energy technologies, and address climate change through carbon sequestration, renewable fuel production, and clean energy manufacturing. These tax expenditures will also lower the cost to households and businesses of investing in energy efficiency and purchasing electric vehicles.


The other one-third of the legislation's clean energy and climate investments represent appropriations by the federal government. These include funds to support conservation practices that will help mitigate emissions from agriculture and forestry. Grants, rebates and federal procurement will promote the adoption of clean energy technologies, as well as energy efficiency improvements in housing. The legislation also invests in the climate resilience of at-risk communities and addresses air pollution.

The climate policies in the Inflation Reduction Act will meaningfully reduce carbon emissions, and thus the acute and chronic physical risks and economic losses resulting from climate change. Physical risks result from inaction on addressing climate change and global temperature rise, which cause serious changes in the physical world. Acute physical risks are natural disasters such as hurricanes, wildfires and floods, which are occurring more frequently and with greater intensity because of rising temperatures. These disasters cause large economic losses, only some of which are insured, pressuring governments to provide disaster relief. Chronic physical risks are the fallout of rising temperatures over longer periods of time, often decades, and include sea level rise caused in part by melting polar ice caps, and oppressive heat. Chronic physical risks

weigh on labor force productivity growth; have serious consequences for agriculture, tourism and other industries; and cause significant changes in global immigration.

We estimate the reduction in CO₂ emissions due to provisions in the Inflation Reduction Act based on work done by the REPEAT project. By 2050, we estimate emissions will be reduced by nearly 30% compared with a scenario in which there is no additional policy changes to address climate change (see Chart 2). This is not quite as much as would have occurred if the \$555 billion in clean energy spending from the original BBB proposal had become law, but it is substantial.

Chart 2: Lower Carbon Emissions Under the Inflation Reduction Act



Sources: EIA, REPEAT, Moody's Analytics


The Inflation Reduction Act also mitigates the economic cost of inaction. Compared with the scenario where no additional climate change action is taken by government, real GDP is approximately 0.1% higher a decade from now because of the Inflation Reduction Act, 0.6% higher by 2050, and 2.7% higher by 2100 (see Chart 3). The clear lesson is that upfront investments in addressing climate change reap substantial long-term economic benefits.

Healthcare

The Inflation Reduction Act also extends enhancements to the Affordable Care Act provided in last year's pandemic relief package, the American Rescue Plan. The ARP expanded eligibility for the premium tax credits to Americans with incomes above 400% of the federal poverty level to purchase health insurance on ACA marketplaces. The law also increased the size of the premium subsidies, thereby reducing or eliminating out-of-pocket premiums for millions of ACA enrollees. Under current law, these enhancements to the premium tax credits expire at the end of this year; the Inflation Reduction Act would extend them through 2025 at a 10-year cost of some \$64 billion.

According to the Urban Institute, if the enhanced premium tax credits lapse as in current law, the number of uninsured people will increase by more than 3 million, and these individuals will consume less healthcare than if they remained insured, contributing to a more than \$11 billion hit to spending on health services and goods. Moreover, those who continue to buy insurance on the ACA marketplaces, typically with incomes of

Chart 3: The Economic Cost of Climate Inaction Is Severe



Sources: Aon, NGFS, Moody's Analytics

between 150% and 400% of the federal poverty level, would see their insurance premiums more than double, making it cost prohibitive for many.


Taxes on corporations and the wealthy

To pay for the investments in the Inflation Reduction Act, large corporations and wealthy, high-income taxpayers will pay more taxes. Most significantly, some \$313 billion over 10 years in revenues would come from a new 15% minimum tax on book income for large companies that report large profits to investors but have little or no taxable profits. There will also be stiffer tax enforcement by the Internal Revenue Service to ensure greater taxpayer compliance at a time when the tax gap—the difference between the taxes owed under law and revenue collected—is large and increasing. On net, stronger IRS enforcement will reduce the cumulative deficit by \$124 billion over 10 years. The legislation will also tax more carried interest that general partners of investment funds receive for implementing investment management services as ordinary income, raising \$13 billion in additional revenue over 10 years.

The tax increases included in the Inflation Reduction Act will weigh on economic growth, all else being equal, but the impact will be small. Though the tax increases being considered are the most meaningful ones since the early 1990s, they are still modest from a historical perspective (see Chart 4).


The tax increases on large corporations will also not appreciably hurt economic growth. This conclusion is supported by the experience with the large tax cuts corporations received under the Tax Cuts and Jobs Act of 2017. This includes the reduction in the top marginal corporate tax rate from 35% to 21%. There is little evidence that the TCJA led to a meaningful sustained increase in business investment, hiring or wages, or prompted businesses to shift production to the U.S. from overseas as intended. Although it is difficult to disentangle all that is going on in the economy to isolate the impacts of the TCJA, it is also difficult to conclude that the TCJA's tax cuts have meaningfully supported a stronger economy. Therefore, the corporate tax increases in the Inflation Reduction Act should not have an appreciable impact on the economy, especially given that the effective corporate tax rate has steadily declined for decades and is close to a record low (see Chart 5).

Chart 4: Tax Increases Will Not Be Overly Burdensome on U.S. Economy



Sources: Romer & Romer, U.S. Treasury, Moody's Analytics

Chart 5: Effective Corporate Tax Rate Is Low and Has Steadily Fallen



Sources: BEA, Moody's Analytics

Prescription drug savings

Besides higher taxes on large corporations and well-to-do households, the Inflation Reduction Act includes several provisions that will, on net, reduce federal healthcare costs. Most notably, it allows Medicare to negotiate lower prices for single-source prescription drugs—drugs only available as the original brand without competing generic equivalents from other manufacturers—on which it spends the most. From 2026 to 2029, the number of important drugs subject to negotiations with Medicare would double from 10 to 20.

In addition, the legislation will require drug companies that raise prices for Medicare and private insurance more quickly than the rate of inflation to pay rebates to the federal government to cover the difference. Other prescription drug savings would come from repealing a Trump-era rule that will eliminate legal safe harbor from a federal anti-kickback law for rebates paid by pharmaceutical manufacturers to health plans and phar-

macy benefit managers in Medicare Part D. Other smaller but meaningful changes to Medicare will include capping annual out-of-pocket drug expenses for enrollees to \$2,000; making vaccines free; and expanding eligibility for the Low-Income Subsidy, which helps beneficiaries pay for prescription drugs. Taken together, these policy changes will cumulatively reduce the nation's budget deficits by \$288 billion over the next decade.

Macroeconomic impact

As named, the Inflation Reduction Act will modestly reduce inflation over the 10-year budget horizon. By the fourth quarter of 2031, the consumer price inflation index will be 0.33% lower because of the legislation (see Table 2). This translates into a reduction in CPI inflation of 3.3 basis points per annum on

Table 2: Inflation and GDP Impact of the Inflation Reduction Act

	Consumer Price Index (1982-84=100)			Real GDP (2012\$ bil)		
	Baseline	Inflation Reduction Act	% difference	Baseline	Inflation Reduction Act	% difference
2022Q1	284.6	284.6	0.00	19,727.9	19,727.9	0.00
2022Q2	290.9	290.9	0.00	19,705.4	19,705.4	0.00
2022Q3	293.7	293.7	0.00	19,824.5	19,824.5	0.00
2022Q4	296.1	296.1	0.00	19,922.8	19,923.2	0.00
2023Q1	298.0	298.0	-0.00	20,007.7	20,009.3	0.01
2023Q2	299.7	299.7	-0.00	20,100.5	20,102.3	0.01
2023Q3	301.2	301.2	-0.01	20,220.9	20,220.3	-0.00
2023Q4	302.6	302.5	-0.01	20,355.0	20,349.2	-0.03
2024Q1	304.3	304.3	-0.01	20,505.6	20,493.6	-0.06
2024Q2	306.0	306.0	-0.01	20,651.7	20,634.2	-0.08
2024Q3	307.8	307.8	-0.01	20,794.8	20,774.5	-0.10
2024Q4	309.7	309.6	-0.01	20,934.6	20,916.8	-0.09
2025Q1	311.5	311.4	-0.02	21,066.0	21,055.0	-0.05
2025Q2	313.2	313.2	-0.02	21,203.5	21,201.0	-0.01
2025Q3	315.0	315.0	-0.02	21,342.2	21,346.7	0.02
2025Q4	316.8	316.7	-0.03	21,491.0	21,499.0	0.04
2026Q1	318.6	318.5	-0.04	21,640.2	21,648.2	0.04
2026Q2	320.4	320.3	-0.05	21,784.9	21,791.5	0.03
2026Q3	322.2	322.0	-0.06	21,926.9	21,932.3	0.02
2026Q4	324.0	323.7	-0.08	22,068.3	22,074.5	0.03
2027Q1	325.6	325.3	-0.09	22,206.9	22,216.4	0.04
2027Q2	327.3	327.0	-0.10	22,339.1	22,352.8	0.06
2027Q3	329.0	328.6	-0.12	22,477.7	22,495.6	0.08
2027Q4	330.8	330.3	-0.13	22,617.8	22,638.9	0.09
2028Q1	332.5	332.0	-0.15	22,754.9	22,778.4	0.10
2028Q2	334.3	333.7	-0.16	22,892.1	22,917.7	0.11
2028Q3	336.1	335.5	-0.18	23,030.3	23,058.2	0.12
2028Q4	337.9	337.2	-0.19	23,166.5	23,195.8	0.13
2029Q1	339.7	339.0	-0.20	23,299.3	23,329.9	0.13
2029Q2	341.5	340.7	-0.22	23,430.5	23,461.9	0.13
2029Q3	343.3	342.5	-0.23	23,560.7	23,592.7	0.14
2029Q4	345.2	344.3	-0.25	23,688.2	23,720.6	0.14
2030Q1	347.0	346.1	-0.26	23,812.8	23,845.9	0.14
2030Q2	348.9	348.0	-0.27	23,936.5	23,971.0	0.14
2030Q3	350.9	349.9	-0.28	24,059.9	24,096.4	0.15
2030Q4	352.8	351.7	-0.29	24,184.2	24,223.1	0.16
2031Q1	354.7	353.7	-0.30	24,309.0	24,350.5	0.17
2031Q2	356.7	355.6	-0.31	24,435.9	24,480.2	0.18
2031Q3	358.6	357.5	-0.32	24,565.2	24,611.9	0.19
2031Q4	360.6	359.4	-0.33	24,692.2	24,740.7	0.20

Sources: BLS, BEA, Moody's Analytics

average over the period. Through the middle of this decade the impact of the legislation on inflation is marginal, but it becomes more meaningful later in the decade.

The legislation weighs on inflation in several ways. Most immediately is through fiscal restraint, as the budget deficit narrows largely because of the taxes on corporations, and results in slower growth. The impact on inflation is small, however, as these growth effects are small. Moreover, large corporations will attempt to pass through some of their higher tax bill to consumers in higher prices for their wares—this will be difficult in competitive markets. The extension of the ACA premium tax credits is also important to quickly reducing inflation, as health insurance costs will rise next year for millions of Americans without the extension.

Weighing on inflation by mid-decade are the reforms to Medicare drug pricing, most importantly being Medicare's ability to negotiate drug prices with pharmaceutical companies. The climate change provisions in the legislation become an increasing headwind to inflation later in the decade. The energy provisions in the Inflation Reduction Act, for example, could reduce the typical American household's spending on energy by an estimated more than \$300 per year in today's dollars. Lower property and casualty insurance rates for businesses and homeowners and flood insurance for households due to the reduction in emissions and physical risk also lean against inflation.

The Inflation Reduction Act will also add to real GDP over the 10-year horizon, although here too the impacts will be small, adding an estimated 0.2% to the level of real GDP by the fourth quarter of 2031. This translates into 2 basis points of growth per annum on average over the period. The impact on GDP is on the margin, even a bit negative, through mid-decade, but turns meaningfully positive in the second half of the decade.

Conclusion

It appears increasingly likely that the Inflation Reduction Act will get through the budget reconciliation process requiring all 50 Senate Democrats to vote for the legislation and become law. The legislation marks a major breakthrough in an arduous series of more than yearlong negotiations between Senate Democrats over passing some form of Biden's Build Back Better agenda. Up until this past week the negotiations had seemingly collapsed. Moody's Analytics will likely incorporate its provisions into the August 2022 baseline (most likely) forecast for the U.S. economy.

The Inflation Reduction Act is much smaller in scale and scope than the original Build Back Better agenda from which it comes. Regardless, it will have a material beneficial economic impact. Most immediately it provides financial help to millions of lower-income and elderly Americans with their health insurance premiums and prescription drug costs. It is also the first meaningful effort by the federal government to address climate change and its long-run corrosive economic effects. Moreover, all of this is more than paid for and will thus reduce the government's future budget deficits, which seems sure to soon become a more pressing economic problem. While modest legislation, there is plenty to like in the Inflation Reduction Act.

About the Authors

Mark Zandi is chief economist of Moody's Analytics, where he directs economic research. Moody's Analytics, a subsidiary of Moody's Corp., is a leading provider of economic research, data and analytical tools. Dr. Zandi is a cofounder of Economy.com, which Moody's purchased in 2005.

Dr. Zandi is on the board of directors of MGIC, the nation's largest private mortgage insurance company, and is the lead director of Reinvestment Fund, one of the nation's largest community development financial institutions, which makes investments in underserved communities.

He is a trusted adviser to policymakers and an influential source of economic analysis for businesses, journalists and the public. Dr. Zandi frequently testifies before Congress and conducts regular briefings on the economy for corporate boards, trade associations, and policymakers at all levels. He is often quoted in national and global publications and interviewed by major news media outlets, and is a frequent guest on CNBC, NPR, Meet the Press, CNN, and various other national networks and news programs.

Dr. Zandi is the author of *Paying the Price: Ending the Great Recession and Beginning a New American Century*, which provides an assessment of the monetary and fiscal policy response to the Great Recession. His other book, *Financial Shock: A 360° Look at the Subprime Mortgage Implosion, and How to Avoid the Next Financial Crisis*, is described by the New York Times as the "clearest guide" to the financial crisis.

Dr. Zandi earned his BS from the Wharton School at the University of Pennsylvania and his PhD at the University of Pennsylvania.

Bernard Yaros is an assistant director and economist at Moody's Analytics focused primarily on federal fiscal policy. He is responsible for maintaining the Moody's Analytics forecast models for federal government fiscal conditions and presidential elections, as well as providing real-time economic analysis on fiscal policy developments coming out of Capitol Hill. Besides fiscal policy, Bernard covers the District of Columbia and Puerto Rico and develops forecasts for Switzerland.

Bernard holds an MSc in international trade, finance and development from the Barcelona Graduate School of Economics and a BA in political economy from Williams College.

Chris Lafakis is a director at Moody's Analytics. He oversees the Moody's Analytics climate risk initiative, and is responsible for climate modeling and scenario creation. He also has expertise in macroeconomics, energy economics, model development and model validation.

Based in West Chester PA, he also contributes to Economic View. Mr. Lafakis has been quoted by media outlets including The Wall Street Journal, CNBC, Bloomberg, and National Public Radio and often speaks at economic conferences and events. Mr. Lafakis received his bachelor's degree in economics from the Georgia Institute of Technology and his master's degree in economics from the University of Alabama.

About Moody's Analytics

Moody's Analytics provides financial intelligence and analytical tools supporting our clients' growth, efficiency and risk management objectives. The combination of our unparalleled expertise in risk, expansive information resources, and innovative application of technology helps today's business leaders confidently navigate an evolving marketplace. We are recognized for our industry-leading solutions, comprising research, data, software and professional services, assembled to deliver a seamless customer experience. Thousands of organizations worldwide have made us their trusted partner because of our uncompromising commitment to quality, client service, and integrity.

Concise and timely economic research by Moody's Analytics supports firms and policymakers in strategic planning, product and sales forecasting, credit risk and sensitivity management, and investment research. Our economic research publications provide in-depth analysis of the global economy, including the U.S. and all of its state and metropolitan areas, all European countries and their subnational areas, Asia, and the Americas. We track and forecast economic growth and cover specialized topics such as labor markets, housing, consumer spending and credit, output and income, mortgage activity, demographics, central bank behavior, and prices. We also provide real-time monitoring of macroeconomic indicators and analysis on timely topics such as monetary policy and sovereign risk. Our clients include multinational corporations, governments at all levels, central banks, financial regulators, retailers, mutual funds, financial institutions, utilities, residential and commercial real estate firms, insurance companies, and professional investors.

Moody's Analytics added the economic forecasting firm Economy.com to its portfolio in 2005. This unit is based in West Chester PA, a suburb of Philadelphia, with offices in London, Prague and Sydney. More information is available at www.economy.com.

Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Further information is available at www.moodyanalytics.com.

DISCLAIMER: Moody's Analytics, a unit of Moody's Corporation, provides economic analysis, credit risk data and insight, as well as risk management solutions. Research authored by Moody's Analytics does not reflect the opinions of Moody's Investors Service, the credit rating agency. To avoid confusion, please use the full company name "Moody's Analytics", when citing views from Moody's Analytics.

About Moody's Corporation

Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). MCO reported revenue of \$6.2 billion in 2021, employs more than 13,000 people worldwide and maintains a presence in more than 40 countries. Further information about Moody's Analytics is available at www.moodyanalytics.com.

© 2022 Moody's Corporation, Moody's Investors Service, Inc., Moody's Analytics, Inc. and/or their licensors and affiliates (collectively, "MOODY'S"). All rights reserved.

CREDIT RATINGS ISSUED BY MOODY'S CREDIT RATINGS AFFILIATES ARE THEIR CURRENT OPINIONS OF THE RELATIVE FUTURE CREDIT RISK OF ENTITIES, CREDIT COMMITMENTS, OR DEBT OR DEBT-LIKE SECURITIES, AND MATERIALS, PRODUCTS, SERVICES AND INFORMATION PUBLISHED BY MOODY'S (COLLECTIVELY, "PUBLICATIONS") MAY INCLUDE SUCH CURRENT OPINIONS. MOODY'S DEFINES CREDIT RISK AS THE RISK THAT AN ENTITY MAY NOT MEET ITS CONTRACTUAL FINANCIAL OBLIGATIONS AS THEY COME DUE AND ANY ESTIMATED FINANCIAL LOSS IN THE EVENT OF DEFAULT OR IMPAIRMENT. SEE APPLICABLE MOODY'S RATING SYMBOLS AND DEFINITIONS PUBLICATION FOR INFORMATION ON THE TYPES OF CONTRACTUAL FINANCIAL OBLIGATIONS ADDRESSED BY MOODY'S CREDIT RATINGS. CREDIT RATINGS DO NOT ADDRESS ANY OTHER RISK, INCLUDING BUT NOT LIMITED TO: LIQUIDITY RISK, MARKET VALUE RISK, OR PRICE VOLATILITY. CREDIT RATINGS, NON-CREDIT ASSESSMENTS ("ASSESSMENTS"), AND OTHER OPINIONS INCLUDED IN MOODY'S PUBLICATIONS ARE NOT STATEMENTS OF CURRENT OR HISTORICAL FACT. MOODY'S PUBLICATIONS MAY ALSO INCLUDE QUANTITATIVE MODEL-BASED ESTIMATES OF CREDIT RISK AND RELATED OPINIONS OR COMMENTARY PUBLISHED BY MOODY'S ANALYTICS, INC. AND/OR ITS AFFILIATES. MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT CONSTITUTE OR PROVIDE INVESTMENT OR FINANCIAL ADVICE, AND MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS ARE NOT AND DO NOT PROVIDE RECOMMENDATIONS TO PURCHASE, SELL, OR HOLD PARTICULAR SECURITIES. MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS DO NOT COMMENT ON THE SUITABILITY OF AN INVESTMENT FOR ANY PARTICULAR INVESTOR. MOODY'S ISSUES ITS CREDIT RATINGS, ASSESSMENTS AND OTHER OPINIONS AND PUBLISHES ITS PUBLICATIONS WITH THE EXPECTATION AND UNDERSTANDING THAT EACH INVESTOR WILL, WITH DUE CARE, MAKE ITS OWN STUDY AND EVALUATION OF EACH SECURITY THAT IS UNDER CONSIDERATION FOR PURCHASE, HOLDING, OR SALE.

MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS, AND PUBLICATIONS ARE NOT INTENDED FOR USE BY RETAIL INVESTORS AND IT WOULD BE RECKLESS AND INAPPROPRIATE FOR RETAIL INVESTORS TO USE MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS OR PUBLICATIONS WHEN MAKING AN INVESTMENT DECISION. IF IN DOUBT YOU SHOULD CONTACT YOUR FINANCIAL OR OTHER PROFESSIONAL ADVISER.

ALL INFORMATION CONTAINED HEREIN IS PROTECTED BY LAW, INCLUDING BUT NOT LIMITED TO, COPYRIGHT LAW, AND NONE OF SUCH INFORMATION MAY BE COPIED OR OTHERWISE REPRODUCED, REPACKAGED, FURTHER TRANSMITTED, TRANSFERRED, DISSEMINATED, REDISTRIBUTED OR RESOLD, OR STORED FOR SUBSEQUENT USE FOR ANY SUCH PURPOSE, IN WHOLE OR IN PART, IN ANY FORM OR MANNER OR BY ANY MEANS WHATSOEVER, BY ANY PERSON WITHOUT MOODY'S PRIOR WRITTEN CONSENT.

MOODY'S CREDIT RATINGS, ASSESSMENTS, OTHER OPINIONS AND PUBLICATIONS ARE NOT INTENDED FOR USE BY ANY PERSON AS A BENCHMARK AS THAT TERM IS DEFINED FOR REGULATORY PURPOSES AND MUST NOT BE USED IN ANY WAY THAT COULD RESULT IN THEM BEING CONSIDERED A BENCHMARK.

All information contained herein is obtained by MOODY'S from sources believed by it to be accurate and reliable. Because of the possibility of human or mechanical error as well as other factors, however, all information contained herein is provided "AS IS" without warranty of any kind. MOODY'S adopts all necessary measures so that the information it uses in assigning a credit rating is of sufficient quality and from sources MOODY'S considers to be reliable including, when appropriate, independent third-party sources. However, MOODY'S is not an auditor and cannot in every instance independently verify or validate information received in the rating process or in preparing its Publications.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability to any person or entity for any indirect, special, consequential, or incidental losses or damages whatsoever arising from or in connection with the information contained herein or the use of or inability to use any such information, even if MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers is advised in advance of the possibility of such losses or damages, including but not limited to: (a) any loss of present or prospective profits or (b) any loss or damage arising where the relevant financial instrument is not the subject of a particular credit rating assigned by MOODY'S.

To the extent permitted by law, MOODY'S and its directors, officers, employees, agents, representatives, licensors and suppliers disclaim liability for any direct or compensatory losses or damages caused to any person or entity, including but not limited to by any negligence (but excluding fraud, willful misconduct or any other type of liability that, for the avoidance of doubt, by law cannot be excluded) on the part of, or any contingency within or beyond the control of, MOODY'S or any of its directors, officers, employees, agents, representatives, licensors or suppliers, arising from or in connection with the information contained herein or the use of or inability to use any such information.

NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY CREDIT RATING, ASSESSMENT, OTHER OPINION OR INFORMATION IS GIVEN OR MADE BY MOODY'S IN ANY FORM OR MANNER WHATSOEVER.

Moody's Investors Service, Inc., a wholly-owned credit rating agency subsidiary of Moody's Corporation ("MCO"), hereby discloses that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by Moody's Investors Service, Inc. have, prior to assignment of any credit rating, agreed to pay to Moody's Investors Service, Inc. for credit ratings opinions and services rendered by it fees ranging from \$1,000 to approximately \$5,000,000. MCO and Moody's Investors Service also maintain policies and procedures to address the independence of Moody's Investors Service credit ratings and credit rating processes. Information regarding certain affiliations that may exist between directors of MCO and rated entities, and between entities who hold credit ratings from Moody's Investors Service and have also publicly reported to the SEC an ownership interest in MCO of more than 5%, is posted annually at www.moody's.com under the heading "Investor Relations — Corporate Governance — Director and Shareholder Affiliation Policy."

Additional terms for Australia only: Any publication into Australia of this document is pursuant to the Australian Financial Services License of MOODY'S affiliate, Moody's Investors Service Pty Limited ABN 61 003 399 657AFSL 336969 and/or Moody's Analytics Australia Pty Ltd ABN 94 105 136 972 AFSL 383569 (as applicable). This document is intended to be provided only to "wholesale clients" within the meaning of section 761G of the Corporations Act 2001. By continuing to access this document from within Australia, you represent to MOODY'S that you are, or are accessing the document as a representative of, a "wholesale client" and that neither you nor the entity you represent will directly or indirectly disseminate this document or its contents to "retail clients" within the meaning of section 761G of the Corporations Act 2001. MOODY'S credit rating is an opinion as to the creditworthiness of a debt obligation of the issuer, not on the equity securities of the issuer or any form of security that is available to retail investors.

Additional terms for Japan only: Moody's Japan K.K. ("MJJK") is a wholly-owned credit rating agency subsidiary of Moody's Group Japan G.K., which is wholly-owned by Moody's Overseas Holdings Inc., a wholly-owned subsidiary of MCO. Moody's SF Japan K.K. ("MSFJ") is a wholly-owned credit rating agency subsidiary of MJJK. MSFJ is not a Nationally Recognized Statistical Rating Organization ("NRSRO"). Therefore, credit ratings assigned by MSFJ are Non-NRSRO Credit Ratings. Non-NRSRO Credit Ratings are assigned by an entity that is not a NRSRO and, consequently, the rated obligation will not qualify for certain types of treatment under U.S. laws. MJJK and MSFJ are credit rating agencies registered with the Japan Financial Services Agency and their registration numbers are FSA Commissioner (Ratings) No. 2 and 3 respectively.

MJJK or MSFJ (as applicable) hereby disclose that most issuers of debt securities (including corporate and municipal bonds, debentures, notes and commercial paper) and preferred stock rated by MJJK or MSFJ (as applicable) have, prior to assignment of any credit rating, agreed to pay to MJJK or MSFJ (as applicable) for credit ratings opinions and services rendered by it fees ranging from JPY100,000 to approximately JPY550,000,000.

MJJK and MSFJ also maintain policies and procedures to address Japanese regulatory requirements.